Prospects for the diagnosis and treatment of plasmalogen deficiency
https://doi.org/10.21508/1027-4065-2021-66-4-16-24
Abstract
The review presents data on the biological significance of plasmalogens, their synthesis in peroxisomes, subsequent transformation cascade, and the relevance of their role in the pathogenesis of a number of diseases. Plasmalogens, being a unique subclass of glycerophospholipids,play the role of structural proteins, signaling molecules, antioxidants. Deficiency of plasmalogens is known in genetically determined peroxisomal diseases – Refsum’s disease, rhizomelic point chondrodysplasia, Zellweger’s disease, etc. A number of age-related neurodegenerative diseases (Alzheimer’s, Parkinson’s) are also characterized by a decrease in the level of plasmalogens due to impaired synthesis and / or acceleration of their biodegradation. Along with the endogenous reasons for the decrease in the level of plasmalogens the authors consider the mechanism of their insufficient synthesis by anaerobes of the intestinal microbiota. These findings reinforce the clinicalrelevanceof the microbiota-gut-brain axis. Many companies allover the world develop drugs and biologically active additives (dietary supplements) with a high content of plasmalogens, being adsorbedin the small intestine and entering the targettissues and organs. The authors emphasizethe prospects of studying metabolites of intestinal microorganisms, directly or indirectly affecting developmental disorders in children, in particular, autism spectrum diseases.
About the Authors
S. I. Polyakova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
G. V. Zasurtsev
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
P. V. Parshina
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
B. A. Kobrinskiy
Pirogov Russian National Research Medical University; Federal Research Center of Computer Science and Control
Russian Federation
Russian Federation
Moscow
References
1. Goldfine H. The appearance, disappearance, and reappearance of plasmalogens in evolution. Progress in Lipid Research 2010; 49(4): 493–498. DOI: 10.1016/j.plipres.2010.07.003
2. Braverman N.E., Moser A.B. Functions of plasmalogen lipids in health and disease. Biochim Biophys Acta 2012; 1822(9): 1442–1452. DOI: 10.1016/j.bbadis.2012.05.008
3. Электронный ресурс. https://en.wikipedia.org/wiki/Plasmalogen#History (Ссылка активна на 17.03.2021.)
4. De Duve C. The peroxisome: a new cytoplasmic organelle. Proceedings of the Royal Society of London. Series B, Biological Sciences. 1969; 173(1030): 71–83. DOI: 10.1098/rspb.1969.0039
5. Nagan N., Zoeller R.A. Plasmalogens: biosynthesis and functions. Prog Lipid Res 2001; 40(3): 199–229. DOI: 10.1016/s0163-7827(01)00003-0
6. Petrov A.M., Zefirov A.L. Holesterol and lipid rafts in the biological membranes. Role in the release, reception and ion channel function. Uspekhi phisiogicheskikh nauk 2013; 44(1): 17–38 (in Russ.)
7. Dean J.M., Lodhi I.J. Structural and functional roles of ether lipids. Protein Cell 2018; 9(2): 196–206. DOI: 10.1007/s13238-017-0423-5
8. Berger J., Dorninger F., Forss-Petter S., Kunze M. Peroxisomes in brain development and function. Biochem Biophys Acta 2016; 1863(5): 934–955. DOI: 10.1016/j.bbamcr.2015.12.005
9. O’Mahony S.M., Clarke G., Dinan T.G., Cryan J.F. Early-life adversity and brain development: Is the microbiome a missing piece of the puzzle. Neuroscience 2017; 342: 37–54. DOI: 10.1016/j.neuroscience.2015.09.068
10. Poitelon Y., KopecA.M., Belin S. Myelin Fat Facts: An Overview of Lipids and Fatty Acid Metabolism. Cells 2020; 9(4): 812–830. DOI: 10.3390/cells9040812
11. Kimura T., Kimura A.K., Ren M., Monteiro V., Xu Y., Berno B. et al. Plasmalogen loss caused by remodeling deficiency in mitochondria. Life Sci Alliance 2019; 2(4): e201900348. DOI: 10.26508/lsa.201900348
12. Goodenowe D.B., Cook L.L., Liu J., Lu Y., Jayasinghe D.A., Ahiahonu P.W. et al. Peripheral plasmalogen deficiency: a logical causative factor in Alzheimer’s disease and dementia. J Lipid Res 2007; 48(11): 2485–2498. DOI: 10.1194/jlr.P700023-JLR200
13. Chew H., Solomon V.A., Fonteh A.N. Involvement of Lipids in Alzheimer’s Disease Pathology and Potential Therapies. Front Physiol 2020; 11: 598. DOI: 10.3389/fphys.2020.00598
14. Okumoto K., Tamura S., Honsho M., Fujiki Y. Peroxisome: Metabolic Functions and Biogenesis. Adv Exp Med Biol 2020; 1299: 3–17. DOI: 10.1007/978-3-030-60204-8_1
15. Farooqui A.A., Horrocks L.A. Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia. Neuroscientist 2001; 7(3): 232–245. DOI: 10.1177/107385840100700308
16. Waterham H.R., Ferdinandusse S., WandersR.J. Human disorders of peroxisome metabolism and biogenesis. Biochem Bio-phys Acta 2016; 1863(5): 922–933. DOI: 10.1016/j.bbamcr.2015.11.015
17. Электронный ресурс. Lipid maps http://cmapspublic3.ihmc.us/rid=1226190639421_1860994023_477/lipids.cmap?rid=1226190639421_1860994023_477&partName=htmljpeg (Ссылка активна на 09.03.2021.)
18. Wanders R.J., Brites P. Biosynthesis of ether-phospholipids including plasmalogens, peroxisomes and human disease: new insights into an old problem. Clin Lipidol 2010; 5(3): 379–386. DOI: 10.2217/clp.10.16
19. Sutter I., Klingenberg R., Othman A., Rohrer L., Landmes ser U., Heg D. et al. Decreased phosphatidylcholine plasmalogens-a putative novel lipid signature in patients with stable coronary artery disease and acute myocardial infarction. Atherosclerosis 2016; 246: 130–140. DOI: 10.1016/j.atherosclerosis.2016.01.003
20. Da Silva T.F., Eira J., Lopes A.T., Malheiro A.R., Sousa V., Luoma A. et al. Peripheral nervous system plasmalogens regulate Schwann cell differentiation and myelination. J Clin Invest 2014; 124(6): 2560–2570. DOI: 10.1172/JCI72063
21. Plasmalogens https://med-life.ca/plasmalogens (Ссылка активна на 09.03.2021.)
22. Wood P.L., Amin Khan M., Mankidy R., Smith T., Goodenowe D.B. Plasmalogen Deficit: A New and Testable Hypothesis for the Etiology of Alzheimer’s Disease. Alzheimer’s Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets. S. De La Monte (ed.). London, 2011; 24. DOI: 10.5772/951
23. Wood P.L., Mankidy R., Ritchie S., Heath D., Wood J.A., Flax J., Goodenowe D.B. Circulating plasmalogen levels and Alzheimer’s disease assessment scale-cognitive scores in Alzheimer patients. J. Psychiatry Neurosci. 2010; 35(1): 59–62. DOI: 10.1503/jpn.090059
24. Dorninger F., Forss-Petter S., Wimmer I., Berger J. Plasmalogens, platelet-activating factor and beyond – Ether lipids in signaling and neurodegeneration. Neurobiol Dis 2020; 145: 105061. DOI: 10.1016/j.nbd.2020.105061
25. Klouwer F.C., Huffnagel I.C., Ferdinandusse S., Water-ham H.R., Wanders R.J., Engelen M., Poll-The B.T. Clinical and Biochemical Pitfalls in the Diagnosis of Peroxisomal Disorders. Neuropediatrics 2016; 47(4): 205–220. DOI: 10.1055/s-0036-1582140
26. Dragonas C., Bertsch T., Sieber C.C., Brosche T. Plasmalo gens as a marker of oxidative stress in Parkinson’s disease. Clin Chem Lab Med 2009; 47: 894–897 DOI: 10.1515/CCLM.2009.205
27. He X., Chen F., McGovern M.M., Schuchman E.H. A fluorescence-based, high-throughput sphingomyelin assay for the analysis of Nieman-Pick disease and other disorders of sphingomyelin metabolism. Anal Biochem 2002; 306(1): 115–123/ DOI: 10.1006/abio.2002.5686
28. Wood P.L, Unfried G., Whitehead W., Phillipps A., Wood J.A. Dysfunctional plasmalogen dynamics in the plasma and platelets of patients with schizophrenia. Schizophr Res 2015; 161(2–3): 506–510. DOI: 10.1016/j.schres.2014.11.032
29. Kaddurah-Daouk R., McEvoyJ., Baillie R., Zhu H., K Yao J., Nimgaonkar V.L. et al. Impaired plasmalogens in patients with schizophrenia. Psychiatry Res 2012; 198(3): 347–352. DOI: 10.1016/j.psychres.2012.02.019
30. Thomas R.H., Foley K.A., Mepham J.R., Tichenoff L.J., Possmayer F., MacFabe D.F. Altered brain phospholipid and acylcarnitine profiles in propionic acid infused rodents: further development of a potential model of autism spectrum disorders. J Neurochem 2010; 113(2): 515–29. DOI: 10.1111/j.1471-4159.2010.06614.x
31. Электронный ресурс. https://www.eurekalert.org/pub_releases/2018-05/asfb-wht052918.php (Ссылка активна на 17.03.2021.)
32. Wiesner P., Leidl K., Boettcher A., SchmitzG., LiebischG. Lipid profiling of FPLC-separated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J Lipid Res 2009; 50(3): 574–585. DOI: 10.1194/jlr.D800028-JLR200
33. Berdyshev E.V. Mass spectrometry of fatty aldehydes. Biochim Biophys Acta 2011; 1811(11): 680–693. DOI: 10.1016/j.bbalip.2011.08.018
34. Griffiths W.J. Tandem mass spectrometry in the study of fatty acids, bile acids, and steroids. Mass Spectrom Rev 2003; 22(2): 81–152. DOI: 10.1002/mas.10046
35. Hui S.P., Chiba H., Kurosawa T. Liquid chromatography-mass spectrometric determination of plasmalogen in human plasma. Anal Bioanal Chem 2011; 400(7): 1923–1931. DOI: 10.1007/s00216-011-4921-7
36. Hidaka H., Yamauchi K., Ohta H., Akamatsu T., Honda T., Katsuyama T. Specific, rapid and sensitive measurement of sphingomyelin, phosphatidylcholine and lysophosphatidylcholine in serum and lipid extracts. Clin Biochem 2008; 41(14_15): 1211–1217. DOI: 10.1016/j.clinbiochem.2008.06.010
37. Goldfine H. Bacterial plasmalogens. Ether lipids: chemistry and biology. F. Snyder (ed.). New York, 1972; 329–350
38. Kamio Y., Kanegasaki S., Takahashi H. Occurrence of Plasmalogens In Anaerobic Bacteria. J Gen Appl Microbiol 1969; 15: 439–451. DOI: 10.2323/jgam.15.439
39. Řezanka T., Křesinová Z., Kolouchová I., Sigler K. Lipidomic analysis of bacterial plasmalogens. Folia Microbiol (Praha) 2012; 57(5): 463–472. DOI: 10.1007/s12223-012-0178-6
40. Mawatari S., Sasuga Y., Morisaki T., Okubo M., Emura T., Fujino T. Identification of plasmalogens in Bifidobacterium longum, but not in Bifidobacterium animalis. Sci Rep 2020; 10(1): 427. DOI: 10.1038/s41598-019-57309-7
41. Hokazono E., Tamezane H., Hotta T., KayamoriY., Osawa S. Enzymatic assay of phosphatidylethanolamine in serum using amine oxidase from Arthrobacter sp. Clin Chim Acta 2011; 412(15–16): 1436–1440. DOI: 10.1016/j.cca.2011.04.023
42. Fallatah W., Smith T., Cui W., Jayasinghe D., Di Pietro E., Ritchie S.A., Braverman N. Oral administration of a synthetic vinyl-ether plasmalogen normalizes open field activity in a mouse model of rhizomelic chondrodysplasia punctate. Dis Model Mech 2020; 13 (1): dmm.042499. DOI: 10.1242/dmm.042499
43. Ulven S.M., Kirkhus B., LamglaitA., Basu S., Elind E., Haider T. et al. Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers. Lipids 2011; 46(1): 37–46. DOI: 10.1007/s11745-010-3490-4
44. Fujino T., Yamada T., Asada T., TsuboiY., Wakana C., Mawatari S., Kono S. Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer’s Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. EBioMedicine 2017; 17: 199–205. DOI: 10.1016/j.ebiom.2017.02.012
45. Paul S., Lancaster G.I., Meikle P.J. Plasmalogens: a potential therapeutic target for neurodegenerative and cardiometabolic disease Prog Lipid Res 2019; 74: 186–195. DOI: 10.1016/j.plipres.2019.04.003
Review
For citations:
Polyakova S.I., Zasurtsev G.V., Parshina P.V., Kobrinskiy B.A. Prospects for the diagnosis and treatment of plasmalogen deficiency. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2021;66(4):16-24. (In Russ.) https://doi.org/10.21508/1027-4065-2021-66-4-16-24
Views:
1193
Email this article 